Pharmaceutical Technology

JANUARY 17, 2023

It could be used for T-Cell Acute Lymphoblastic Leukaemia (T-ALL) treatment in patients for whom bone marrow transplantation and chemotherapy failed to work. By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy.

Hospitals 110

Hospitals Chemotherapy Communication Immunization 110

Pharmaceutical Technology

FEBRUARY 17, 2023

They state that newer drugs like monoclonal antibodies and kinase inhibitors may benefit from a drug optimisation approach due to their different dose escalation profiles, compared to the cytotoxic chemotherapy drugs. Download the full report to understand what to expect and how to align your strategies for success.

Dosage 115

Dosage FDA Pharmaceutical Companies Pharmaceutical Companies 115

Pharmaceutical Technology

JUNE 13, 2023

Common treatment options for the condition include bladder removal surgery, chemotherapy and/or administration of the BCG vaccine in the bladder. Download the full report to understand what to expect and how to align your strategies for success. Please check your email to download the Report.

FDA 98

FDA Vaccines Chemotherapy Communication 98

Pharmaceutical Technology

MAY 31, 2023

Chemotherapy used to treat blood cancer results in increased intestinal permeability, making E. Download the full report to understand what to expect and how to align your strategies for success. Please check your email to download the Report. coli a frequent cause of bloodstream infections that carries a 15-20% fatality rate.

Chemotherapy 98

Chemotherapy FDA Communication Immunization 98

Pharmaceutical Technology

JUNE 16, 2023

Designated as BG01-2202, this latest trial will be an open-label, randomised, controlled clinical study of UTD1 versus chemotherapy drug docetaxel. A Phase III study to evaluate UTD1 versus docetaxel in patients that have failed chemotherapy with a platinum-containing regimen is also currently underway in China. ORR, 81.0%

FDA 52

FDA Chemotherapy Labelling Pharmaceutical Companies 52

Pharmaceutical Technology

JUNE 16, 2023

In 2021, as part of the same Keynote-811 trial, the US Food and Drug Administration (FDA) granted accelerated approval to Keytruda for treating locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma, in combination with trastuzumab and chemotherapy containing fluoropyrimidin and platinum.

Chemotherapy 52

Chemotherapy Labelling FDA Communication 52

Pharmaceutical Technology

JUNE 5, 2023

In results presented at the ongoing American Society of Clinical Oncology (ASCO) Annual Meeting , Summit reported an overall response rate (ORR) of 67% in NSCLC patients with squamous histology treated with its lead drug ivonescimab plus chemotherapy. The treatment had an acceptable safety profile in combination with chemotherapy.

Chemotherapy 52

Chemotherapy Communication 52